List of Excipients in Branded Drug PHENYLEPHRINE HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	PHENYLEPHRINE HYDROCHLORIDE	phenylephrine hydrochloride	0065-0349	BENZALKONIUM CHLORIDE
Alcon Laboratories Inc	PHENYLEPHRINE HYDROCHLORIDE	phenylephrine hydrochloride	0065-0349	PHOSPHORIC ACID
Alcon Laboratories Inc	PHENYLEPHRINE HYDROCHLORIDE	phenylephrine hydrochloride	0065-0349	SODIUM HYDROXIDE
Alcon Laboratories Inc	PHENYLEPHRINE HYDROCHLORIDE	phenylephrine hydrochloride	0065-0349	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS

Generic Drugs Containing PHENYLEPHRINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Henry Schein Inc	phenylephrine hydrochloride	0404-9931	CITRIC ACID MONOHYDRATE
Henry Schein Inc	phenylephrine hydrochloride	0404-9931	HYDROCHLORIC ACID
Henry Schein Inc	phenylephrine hydrochloride	0404-9931	SODIUM CHLORIDE
Henry Schein Inc	phenylephrine hydrochloride	0404-9931	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in PHENYLEPHRINE HYDROCHLORIDE?

# Of NDCs	Excipient
9	BENZALKONIUM CHLORIDE
43	CITRIC ACID MONOHYDRATE
43	HYDROCHLORIC ACID
4	NITROGEN

Last updated: August 16, 2026

Phenylephrine hydrochloride is an off-patent sympathomimetic with limited active-ingredient exclusivity but meaningful formulation and delivery opportunities. The strongest commercial prospects are preservative-free nasal products, stable injectable presentations, differentiated pediatric liquids, and combination products that comply with changing FDA expectations. Oral phenylephrine has a major regulatory risk: FDA proposed removing oral phenylephrine as an OTC monograph ingredient because available data do not support effectiveness at the recommended dose. [1]

Phenylephrine Hydrochloride Excipient Strategy and Commercial Opportunities

What is the commercial status of phenylephrine hydrochloride?

Phenylephrine hydrochloride is an alpha-1 adrenergic receptor agonist used as a nasal decongestant, ophthalmic vasoconstrictor, and injectable vasopressor. The active pharmaceutical ingredient is generic and widely available from multiple suppliers. Commercial differentiation therefore depends on dosage form, excipient selection, device compatibility, stability, preservative strategy, and regulatory positioning.

Product segment	Principal use	Regulatory position	Commercial outlook
Nasal spray or drops	Local nasal congestion	OTC monograph pathway in the U.S.	Viable, but crowded
Oral tablet, capsule, or liquid	Systemic decongestant	FDA proposed removal of oral phenylephrine from OTC monograph	High regulatory risk
Ophthalmic solution	Mydriasis and ocular vasoconstriction	Prescription and institutional products	Stable niche
Injectable solution	Hypotension and vasopressor support	Approved prescription products and generic equivalents	Attractive for ready-to-use presentations
Combination cold product	Congestion with pain, cough, or allergy symptoms	Subject to ingredient-specific FDA requirements	Commercially established but exposed to oral phenylephrine action
Veterinary formulations	Vasoconstrictor and ophthalmic uses	Separate regulatory pathway	Smaller specialty market

Phenylephrine hydrochloride is water soluble and generally suitable for aqueous formulations. The main development issues are pH control, oxidation, light exposure, preservative compatibility, microbial control, container closure, and dose accuracy.

What FDA regulatory status applies to phenylephrine hydrochloride?

Oral phenylephrine

FDA proposed a rule in 2024 to remove oral phenylephrine hydrochloride from the OTC monograph for nasal decongestant use. FDA concluded that oral phenylephrine is not effective at the monograph dose based on a review of clinical pharmacology and efficacy data. The proposal did not apply to intranasal phenylephrine products. [1]

The regulatory consequences are material:

• Oral phenylephrine single-ingredient products cannot rely indefinitely on the existing OTC monograph if FDA finalizes the proposed order.
• Combination products containing oral phenylephrine may require reformulation, removal from the market, or a new drug application.
• Excipients cannot cure a lack of active-ingredient efficacy at the intended route and dose.
• Commercial investment in new oral phenylephrine products has elevated regulatory risk in the United States.

The FDA action concerns efficacy, not a broad finding that phenylephrine hydrochloride is unsafe in every dosage form. Intranasal, injectable, and ophthalmic uses remain distinct regulatory categories.

Intranasal phenylephrine

Intranasal phenylephrine remains commercially relevant because local administration produces a different exposure profile from oral dosing. Common products use 0.25% or 0.5% solutions, depending on the product and patient population. Sponsors must address local tolerability, rebound congestion risk with prolonged use, microbiological quality, dose delivery, and preservative exposure.

Injectable phenylephrine

Phenylephrine hydrochloride injection is used for clinically significant hypotension associated with anesthesia and other hospital settings. FDA-approved products include concentrated vials requiring dilution and ready-to-use presentations. The label for phenylephrine hydrochloride injection identifies sodium chloride, citric acid, sodium citrate, and water for injection in certain formulations, with pH adjustment as applicable. [2]

The injectable market has higher technical and quality barriers than consumer nasal products. Sterility assurance, particulate control, extractables and leachables, endotoxin limits, container closure integrity, and preparation-error reduction create defensible product attributes even where the active ingredient is generic.

What excipient strategy is appropriate for phenylephrine hydrochloride?

The excipient platform should be selected by route, target shelf life, dose volume, patient population, and container system. No single excipient system is optimal across nasal, oral, ophthalmic, and injectable products.

Aqueous pH and buffer systems

Phenylephrine hydrochloride is commonly formulated in acidic aqueous systems. Buffer selection affects chemical stability, nasal or ocular tolerability, preservative performance, and container compatibility.

Potential systems include:

• Citric acid and sodium citrate
• Phosphate buffers
• Acetate buffers
• Hydrochloric acid or sodium hydroxide for pH adjustment
• Unbuffered water systems where the target pH and stability profile permit

A lower pH can improve chemical stability in some formulations, but excessive acidity may increase burning or irritation in nasal and ophthalmic products. Buffer capacity should remain low enough to avoid unnecessary tissue irritation while maintaining stability through the labeled shelf life.

Antioxidants and chelating agents

Oxidative degradation is a central formulation concern for phenylephrine. Sodium metabisulfite, sodium bisulfite, and related sulfite antioxidants may be considered in injectable or ophthalmic products, subject to route-specific tolerability and labeling requirements.

Potential chelators include disodium edetate. Chelation can reduce metal-catalyzed oxidation and may support preservative performance. The benefit must be demonstrated through stressed stability studies because chelators can affect compatibility with manufacturing equipment and container systems.

A sponsor should evaluate:

• Phenylephrine assay and degradant formation
• Color change
• Oxygen sensitivity
• Headspace effects
• Metal ion burden
• Light exposure
• Compatibility with elastomeric closures
• Antioxidant depletion over time

Preservatives

Preservative selection is commercially important in multidose nasal and ophthalmic products.

Common candidates include:

• Benzalkonium chloride
• Phenoxyethanol
• Chlorobutanol
• Benzyl alcohol, where route and patient population permit
• Potassium sorbate or related systems in selected aqueous products

Benzalkonium chloride is widely used but may raise concerns about mucosal irritation and chronic exposure. A preservative-free product can command a premium in selected patient and institutional segments, especially where repeated administration is expected or preservative sensitivity is a purchasing factor.

For multidose nasal sprays, the preservative strategy must be evaluated together with the device. A validated microbiological barrier or one-way valve may reduce or eliminate the need for a conventional preservative. This creates an opportunity for device-led differentiation rather than active-ingredient differentiation.

Tonicity agents

Sodium chloride is the primary tonicity agent in many nasal, ophthalmic, and injectable formulations. Dextrose may be used in certain injectable presentations, depending on the target osmolality and clinical setting.

Tonicity affects:

• Nasal comfort
• Ocular tolerability
• Injection-site tolerability
• Stability
• Infusion compatibility
• Container volume and dose concentration

For nasal products, isotonic or near-isotonic formulations may improve comfort, but tonicity should not compromise chemical stability or preservative performance.

Solubilizers and cosolvents

Phenylephrine hydrochloride is sufficiently water soluble for many immediate-release aqueous products. Cosolvents are therefore usually unnecessary for standard nasal, ophthalmic, and injectable formulations. Their use may complicate tolerability, extractables, regulatory review, and pediatric acceptability.

In oral liquids, glycerin, propylene glycol, polyethylene glycol, or ethanol may be considered to support solubility, taste masking, or preservation. Ethanol is commercially unattractive for pediatric products and should be avoided where a nonalcoholic system provides equivalent performance.

What formulations are protected or commercially differentiated?

Phenylephrine hydrochloride has no meaningful remaining composition-of-matter exclusivity in the United States. Commercial protection must come from formulation, device, manufacturing, regulatory, or branding advantages.

Preservative-free nasal formulations

A preservative-free nasal spray can be differentiated through:

• Unit-dose ampoules
• Metered-dose pumps with microbial protection
• One-way valve systems
• Sterile blow-fill-seal packaging
• Low-irritancy excipient systems
• Improved dose uniformity

The strongest protection is usually a combination of formulation and device claims. A formulation patent alone may be vulnerable if competitors can substitute buffer, preservative, or tonicity agents without changing performance.

Ready-to-use injectable products

Hospital products can be differentiated through:

• Premixed low-dose syringes
• Ready-to-administer bags
• Standardized concentrations
• Extended in-use stability
• Reduced dilution requirements
• Barcoded packaging
• Closed-system transfer compatibility
• Terminal sterilization where feasible

These attributes address medication errors and workflow costs. Commercial value may exceed the value of a lower-cost conventional vial, particularly in anesthesia, emergency medicine, and operating-room settings.

Pediatric oral liquids

Despite oral efficacy concerns, phenylephrine-containing pediatric liquids remain present in some markets and combination products. A sponsor considering this segment faces substantial U.S. regulatory exposure.

Where legally viable, excipient differentiation could include:

• Sugar-free syrups
• Alcohol-free systems
• Dye-free formulations
• Low-sodium systems
• Taste-masked suspensions
• Unit-dose oral syringes
• Child-resistant packaging
• Improved dose metering

The formulation opportunity is commercially weaker in the United States if FDA removes oral phenylephrine from the OTC monograph. It may remain relevant in non-U.S. jurisdictions with different regulatory conclusions.

How many patents cover phenylephrine hydrochloride?

The active ingredient is off patent, and generic competition is extensive. Patent value is concentrated in product-specific claims rather than the molecule.

Relevant claim categories include:

Claim category	Potential scope	Relative defensibility
Specific pH and buffer range	Aqueous nasal, ocular, or injectable solution	Moderate if linked to demonstrated stability
Preservative-free composition	Multidose or unit-dose product	Moderate to strong when combined with device claims
Antioxidant and chelator system	Reduced degradation or discoloration	Moderate
Metered-dose device	Dose accuracy and microbial protection	Stronger if device structure is distinctive
Premixed injectable concentration	Ready-to-use hospital product	Moderate
Taste-masked oral formulation	Consumer or pediatric product	Weak to moderate
Combination cold product	Multiple active ingredients	Usually narrow and crowded
Manufacturing process	Sterile filling, oxygen control, or packaging	Moderate

Patent searches should separate phenylephrine hydrochloride from phenylephrine base, route-specific formulations, combination products, and device patents. A single broad search will overstate the relevant estate.

The practical freedom-to-operate risk is likely to arise from a branded combination product, nasal delivery device, or proprietary ready-to-use injectable rather than from phenylephrine hydrochloride itself. Orange Book-listed patents must be checked at the individual NDA level because a generic API may be unencumbered while a branded formulation remains protected by listed patents.

What is the Orange Book status of phenylephrine products?

The Orange Book is most relevant to approved prescription phenylephrine products and NDA-based combination products. OTC monograph products generally do not rely on Orange Book patent listings in the same way as NDA products.

For prescription products, the commercial review should examine:

• NDA and ANDA product records
• Listed patents and pediatric exclusivity
• Therapeutic equivalence codes
• Patent certifications
• Regulatory exclusivity
• Labeling differences
• Strength and container presentations

Phenylephrine injection generics may enter through ANDAs where the reference product and dosage form support abbreviated approval. The absence of a composition-of-matter patent does not eliminate regulatory barriers involving sterile manufacturing, product-specific labeling, or complex presentations.

When does phenylephrine hydrochloride lose exclusivity?

Phenylephrine hydrochloride has already lost active-ingredient exclusivity in the United States. The relevant commercial dates are therefore product-specific rather than molecule-specific.

Exclusivity type	Status
Compound patent	Expired
Standard generic competition	Established
Oral OTC monograph status	Subject to FDA proposed removal
Injectable product exclusivity	Depends on individual NDA and listed rights
Formulation patent protection	Depends on claim scope and expiration
Device protection	Depends on device patent and regulatory linkage
Pediatric exclusivity	Product-specific, where granted

A generic launch does not require a sponsor to replicate every excipient. It generally requires pharmaceutical equivalence, bioequivalence where applicable, and compliance with the applicable monograph or abbreviated approval pathway. This limits the commercial value of many formulation patents unless they cover a clinically meaningful or technically necessary feature.

Which companies are challenging phenylephrine products?

The main competitive pressure comes from generic manufacturers, OTC brand owners, private-label suppliers, and hospital injectable companies. The market includes large generic manufacturers such as Hikma, Pfizer, Fresenius Kabi, and others in injectable products, while consumer products are sold by major OTC companies and retailers under private-label brands.

Competition is based on:

• Wholesale acquisition price
• Supply reliability
• Shortage performance
• Packaging format
• Device availability
• Retail shelf placement
• Contract manufacturing
• Hospital formulary status
• Combination-product branding

The oral phenylephrine market is particularly exposed to substitution by pseudoephedrine, intranasal decongestants, saline products, and non-decongestant cold remedies. Pseudoephedrine has its own retail and purchase restrictions, which preserve some demand for alternatives.

What patent litigation and Paragraph IV risks affect phenylephrine?

Paragraph IV litigation risk is limited for the basic active ingredient but may arise for NDA-based products with listed formulation, method-of-use, or device patents. A generic applicant may certify that a listed patent is invalid, unenforceable, or not infringed.

Potential litigation triggers include:

• Ready-to-use injectable formulations
• Proprietary concentrations
• Combination products
• Nasal delivery systems
• Preservative-free multidose packaging
• Specific stability or storage claims
• Method-of-use claims tied to a particular clinical setting

For OTC monograph products, Paragraph IV is generally less central than for NDA products. The principal risk is regulatory removal or reformulation rather than patent litigation.

What licensing deals are relevant to phenylephrine hydrochloride?

Licensing value is more likely to attach to enabling technology than to phenylephrine hydrochloride itself. Relevant deal structures include:

• In-licensing of preservative-free nasal devices
• Contract manufacturing and supply agreements
• Hospital injectable co-development
• Private-label OTC manufacturing
• Combination-product rights
• Regional commercialization licenses
• Sterile fill-finish partnerships

A licensor with a validated device, sterile manufacturing platform, or proprietary stability package may obtain better economics than an owner of a broad phenylephrine formulation patent. The commercial value of a license depends on whether the technology improves approval probability, reduces manufacturing cost, or supports premium pricing.

What generic entry risks exist for phenylephrine products?

Generic entry risk is high for conventional tablets, simple oral liquids, nasal drops, and standard injectable vials. It is lower for products requiring specialized packaging, sterile manufacturing, delivery-device integration, or documented extended stability.

High-risk segments

• Immediate-release oral tablets
• Conventional capsules
• Basic oral solutions
• Standard nasal drops
• Simple multidose nasal sprays
• Conventional injectable vials

Lower-risk segments

• Preservative-free metered nasal systems
• Unit-dose sterile nasal products
• Ready-to-use syringes
• Premixed infusion bags
• Products with validated extended in-use stability
• Device-integrated products with workflow benefits

The lower-risk segments still face substitution by alternative phenylephrine presentations. Patent protection alone may not prevent erosion if hospitals or retailers view the product as clinically interchangeable.

How does phenylephrine compare with competing decongestants and vasopressors?

Product	Primary route or use	Key competitive advantage	Key limitation
Phenylephrine	Nasal, ophthalmic, injectable	Established supply chain and vasopressor use	Oral efficacy challenge
Pseudoephedrine	Oral decongestant	Stronger historical oral efficacy support	Sales restrictions and stimulant-related concerns
Oxymetazoline	Intranasal	Long duration of local action	Rebound congestion with overuse
Xylometazoline	Intranasal	Established local decongestant use	Similar duration-of-use concerns
Norepinephrine	Injectable vasopressor	Broad critical-care use	More complex handling and administration
Ephedrine	Injectable and oral uses	Mixed direct and indirect sympathomimetic activity	Safety and supply considerations

Phenylephrine’s most defensible commercial position is injectable hospital use and selected local nasal or ophthalmic products. Its weakest position is oral OTC decongestion in the United States.

What manufacturing and intellectual-property barriers matter?

Manufacturing barriers are more important than API scarcity. A commercial program should prioritize:

1. API impurity and nitrosamine-risk assessment.
2. Oxidation and light-protection studies.
3. Low-oxygen filling and headspace control.
4. Container closure compatibility.
5. Sterile filtration or terminal sterilization strategy.
6. Preservative efficacy testing.
7. Device dose-uniformity testing.
8. Extractables and leachables evaluation.
9. In-use stability after opening.
10. Robust supply of pharmaceutical-grade excipients.

For injectables, the key barrier is validated sterile production at commercial scale. For nasal products, the key barrier is reliable dose delivery and microbiological protection. For oral liquids, taste, dosing accuracy, and regulatory viability matter more than patent scope.

What commercial opportunities remain for phenylephrine hydrochloride?

The highest-value opportunities are:

1. Ready-to-use hospital injectables

A prefilled syringe or standardized premix can reduce preparation time and dosing errors. The product may compete on total workflow cost rather than vial price.

2. Preservative-free nasal delivery

Unit-dose or protected multidose systems can target patients who avoid benzalkonium chloride and institutions seeking reduced preservative exposure.

3. Ophthalmic specialty products

Phenylephrine remains useful in ophthalmic settings where predictable mydriasis and vasoconstriction are required. Preservative-free single-dose products and low-volume containers offer differentiation.

4. International oral formulations

Oral products may retain commercial relevance outside the United States, subject to country-specific efficacy and monograph requirements. A global strategy should avoid assuming that U.S. regulatory treatment applies internationally.

5. Private-label and contract manufacturing

The generic nature of the active ingredient supports retailer and regional-brand products. Margin depends on supply reliability, packaging cost, and regulatory compliance.

Key Takeaways

• Phenylephrine hydrochloride is off-patent, so the active ingredient provides little standalone exclusivity.
• Oral OTC phenylephrine faces a major U.S. regulatory threat after FDA proposed removing it from the OTC monograph for lack of efficacy.
• Intranasal, ophthalmic, and injectable products remain separate commercial and regulatory opportunities.
• The strongest formulation strategy combines oxidation control, low-irritancy excipients, preservative minimization, and validated packaging.
• Ready-to-use injectable products offer the clearest premium opportunity.
• Preservative-free nasal and ophthalmic systems can support formulation and device-based differentiation.
• Patent value is concentrated in delivery devices, sterile presentations, stability systems, and specific combinations.
• Generic entry risk is high for simple dosage forms and lower for specialized sterile or device-integrated products.
• Manufacturing capability, supply reliability, and regulatory pathway selection are more important than API patent ownership.

FAQs

Can excipients restore the efficacy of oral phenylephrine?

No. Excipients can improve dissolution, absorption, taste, stability, or dose uniformity, but they cannot compensate for an active ingredient that FDA determines is ineffective at the intended oral dose.

Is intranasal phenylephrine still a viable product opportunity?

Yes. Intranasal phenylephrine is regulated separately from oral phenylephrine. Opportunities remain in preservative-free, unit-dose, low-irritancy, and device-protected products.

Which excipient is best for stabilizing phenylephrine hydrochloride?

No universal excipient is best. The formulation normally requires a route-specific combination of pH control, antioxidant protection, metal-ion control, light protection, and compatible packaging.

Are phenylephrine hydrochloride injectable products vulnerable to hospital generic substitution?

Yes, particularly for conventional vials. Ready-to-use syringes, premixes, standardized concentrations, and products with documented workflow advantages may reduce direct price substitution.

Can a phenylephrine formulation receive meaningful patent protection?

Yes, but protection is usually narrow. The strongest candidates are specific preservative-free compositions, device-linked systems, ready-to-use sterile presentations, and formulations with demonstrated stability or usability advantages.

References

1. U.S. Food and Drug Administration. (2024). Oral phenylephrine hydrochloride: Proposed order on the effectiveness of oral phenylephrine as an OTC nasal decongestant. https://www.fda.gov/drugs/drug-safety-and-availability/fda-proposes-removal-oral-phenylephrine-otc-monograph

2. DailyMed. (n.d.). Phenylephrine hydrochloride injection prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/

3. U.S. Food and Drug Administration. (2023). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341

5. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention. https://www.usp.org/standards-compendia/fcc-and-usp-nf